Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.2
4.6
Journals
Bioengineering
Special Issues
Novel Advances in Stem Cell Therapy for Neurological Diseases
share announcement

Novel Advances in Stem Cell Therapy for Neurological Diseases

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 9166

Special Issue Editors

Dr. Cecilia Laterza

E-Mail Website
Guest Editor
Department of Industrial Engineering, University of Padova, 35137 Padova, Italy
Interests: stem cell therapy; neurodegenerative diseases; induced pluripotent stem cells; brain organoids; 3D bioprinting
Dr. Daniel Tornero

E-Mail Website
Guest Editor
Department of Biomedical Sciences, University of Barcelona, 08036 Barcelona, Spain
Interests: stem cell therapy, brain damage; induced pluripotent stem cells; stroke; brain-on-chip; functional integration; neuronal networks

Special Issue Information

Dear Colleagues,

The use of stem cells has opened a new perspective for the cure of neurological diseases, considered by many the ultimate challenge for regenerative medicine. The aim of stem cell therapy in the context of neurological disorders is to restore tissue function via reconstructing the lost neuronal circuits. However, to date, their therapeutic contribution is quite exclusively related to their “bystander effect” on remaining healthy tissue, rather than repairing the damaged network because of their limited cell survival, inadequate neuronal differentiation and poor integration in the host neuronal network. So, there is an urgent need to develop multidisciplinary strategies, merging stem cell biology, bioengineering and neuroscience with the common aim of achieving neurological function restoration. This Special Issue of Bioengineering on Novel advances in stem cell therapy for Neurological Diseases addresses the central role in defining the novel approaches developed to improve the efficacy of stem cell-based therapies for neurological disorders by bringing together contributions from worldwide experts on stem cell biology, engineering, biomaterials and stem cell therapy applied to neurological diseases.

Dr. Cecilia Laterza
Dr. Daniel Tornero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stem cell therapy
  • neurological diseases
  • regenerative medicine
  • biomaterials
  • 3D scaffold
  • bioprinting
  • hydrogel
  • bioinks

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3288 KiB  
Article
An In Vivo Platform for Rebuilding Functional Neocortical Tissue
by Alexandra Quezada, Claire Ward, Edward R. Bader, Pavlo Zolotavin, Esra Altun, Sarah Hong, Nathaniel J. Killian, Chong Xie, Renata Batista-Brito and Jean M. Hébert
Bioengineering 2023, 10(2), 263; https://doi.org/10.3390/bioengineering10020263 - 16 Feb 2023
Viewed by 3321
Abstract
Recent progress in cortical stem cell transplantation has demonstrated its potential to repair the brain. However, current transplant models have yet to demonstrate that the circuitry of transplant-derived neurons can encode useful function to the host. This is likely due to missing cell [...] Read more.
Recent progress in cortical stem cell transplantation has demonstrated its potential to repair the brain. However, current transplant models have yet to demonstrate that the circuitry of transplant-derived neurons can encode useful function to the host. This is likely due to missing cell types within the grafts, abnormal proportions of cell types, abnormal cytoarchitecture, and inefficient vascularization. Here, we devised a transplant platform for testing neocortical tissue prototypes. Dissociated mouse embryonic telencephalic cells in a liquid scaffold were transplanted into aspiration-lesioned adult mouse cortices. The donor neuronal precursors differentiated into upper and deep layer neurons that exhibited synaptic puncta, projected outside of the graft to appropriate brain areas, became electrophysiologically active within one month post-transplant, and responded to visual stimuli. Interneurons and oligodendrocytes were present at normal densities in grafts. Grafts became fully vascularized by one week post-transplant and vessels in grafts were perfused with blood. With this paradigm, we could also organize cells into layers. Overall, we have provided proof of a concept for an in vivo platform that can be used for developing and testing neocortical-like tissue prototypes. Full article
(This article belongs to the Special Issue Novel Advances in Stem Cell Therapy for Neurological Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 4946 KiB  
Review
Human Bone Marrow-Derived Mesenchymal Stem Cell Applications in Neurodegenerative Disease Treatment and Integrated Omics Analysis for Successful Stem Cell Therapy
by Seok Gi Kim, Nimisha Pradeep George, Ji Su Hwang, Seokho Park, Myeong Ok Kim, Soo Hwan Lee and Gwang Lee
Bioengineering 2023, 10(5), 621; https://doi.org/10.3390/bioengineering10050621 - 22 May 2023
Cited by 4 | Viewed by 1784
Abstract
Neurodegenerative diseases (NDDs), which are chronic and progressive diseases, are a growing health concern. Among the therapeutic methods, stem-cell-based therapy is an attractive approach to NDD treatment owing to stem cells’ characteristics such as their angiogenic ability, anti-inflammatory, paracrine, and anti-apoptotic effects, and [...] Read more.
Neurodegenerative diseases (NDDs), which are chronic and progressive diseases, are a growing health concern. Among the therapeutic methods, stem-cell-based therapy is an attractive approach to NDD treatment owing to stem cells’ characteristics such as their angiogenic ability, anti-inflammatory, paracrine, and anti-apoptotic effects, and homing ability to the damaged brain region. Human bone-marrow-derived mesenchymal stem cells (hBM-MSCs) are attractive NDD therapeutic agents owing to their widespread availability, easy attainability and in vitro manipulation and the lack of ethical issues. Ex vivo hBM-MSC expansion before transplantation is essential because of the low cell numbers in bone marrow aspirates. However, hBM-MSC quality decreases over time after detachment from culture dishes, and the ability of hBM-MSCs to differentiate after detachment from culture dishes remains poorly understood. Conventional analysis of hBM-MSCs characteristics before transplantation into the brain has several limitations. However, omics analyses provide more comprehensive molecular profiling of multifactorial biological systems. Omics and machine learning approaches can handle big data and provide more detailed characterization of hBM-MSCs. Here, we provide a brief review on the application of hBM-MSCs in the treatment of NDDs and an overview of integrated omics analysis of the quality and differentiation ability of hBM-MSCs detached from culture dishes for successful stem cell therapy. Full article
(This article belongs to the Special Issue Novel Advances in Stem Cell Therapy for Neurological Diseases)
►▼ Show Figures

Graphical abstract

23 pages, 1631 KiB  
Review
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update
by Alice Mariottini, Giovanni Bulgarini, Sara Cornacchini, Valentina Damato, Riccardo Saccardi and Luca Massacesi
Bioengineering 2023, 10(2), 176; https://doi.org/10.3390/bioengineering10020176 - 29 Jan 2023
Cited by 2 | Viewed by 3185
Abstract
Over the last two decades, haematopoietic stem cell transplantation (HSCT) has been explored as a potential therapeutic strategy for autoimmune diseases refractory to conventional treatments, including neurological disorders. Although both autologous (AHSCT) and allogeneic HSCT (allo-HSCT) were investigated, AHSCT was preferentially developed due [...] Read more.
Over the last two decades, haematopoietic stem cell transplantation (HSCT) has been explored as a potential therapeutic strategy for autoimmune diseases refractory to conventional treatments, including neurological disorders. Although both autologous (AHSCT) and allogeneic HSCT (allo-HSCT) were investigated, AHSCT was preferentially developed due to a more favourable safety profile compared to allo-HSCT. Multiple sclerosis (MS) represents the most frequent neurological indication for AHSCT, but increasing evidence on the potential effectiveness of transplant in other autoimmune neurological diseases is emerging, although with a risk-benefit ratio overall more uncertain than in MS. In the present work, the rationale for the use of HSCT in neurological diseases and the experimental models that prompted its clinical application will be briefly covered. Case series and prospective studies exploring the use of HSCT in autoimmune diseases other than MS will be discussed, covering both frequent and rare neurological disorders such as myasthenia gravis, myopathies, and stiff-person syndrome. Finally, an updated summary of ongoing and future studies focusing on this issue will be provided. Full article
(This article belongs to the Special Issue Novel Advances in Stem Cell Therapy for Neurological Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop